The ability to go for a screening at age 40 to determine your predisposed risk of developing Alzheimer’s disease, followed by the option of a vaccine – this is the future AC Immune’s CEO Andrea Pfeifer envisages for AD treatment.
In Vivo spoke to several early- to mid-stage biotechs, finding uniformity in recommendations to advance AD treatment that can be...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?